Evidence map›Paper›PMID 40321178›Full record

ArticleChemical science2025

High-throughput encapsulated nanodroplet screening for accelerated co-crystal discovery.

Jessica P Metherall, Philip A Corner, James F McCabe, Michael R Probert, Michael J Hall

Abstract read
In one paragraph

Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Weak hydrogen bonding in the structures of three double-acylated aminoantipyrines.Acta crystallographica. Section C, Structural chemistry · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jessica P MetherallChemistry, School of Natural and Environmental Sciences, Newcastle University Newcastle upon Tyne UK michael.hall@newcastle.ac.uk.ORCID https://orcid.org/0000-0001-5484-4661
Philip A CornerEarly Product Development & Manufacturing, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca Macclesfield UK.ORCID https://orcid.org/0000-0002-0516-3007
James F McCabeEarly Product Development & Manufacturing, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca Macclesfield UK.ORCID https://orcid.org/0000-0002-6062-2253
Michael R ProbertChemistry, School of Natural and Environmental Sciences, Newcastle University Newcastle upon Tyne UK michael.hall@newcastle.ac.uk.ORCID https://orcid.org/0000-0002-2412-7917
Michael J HallChemistry, School of Natural and Environmental Sciences, Newcastle University Newcastle upon Tyne UK michael.hall@newcastle.ac.uk.ORCID https://orcid.org/0000-0001-6475-9161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Co-crystals are composed of two or more chemically inequivalent molecular species, excluding solvents, generally in a stoichiometric ratio. Co-crystals are particularly important in pharmaceutical development, where a suitable co-crystal can significantly improve the physiochemical and pharmacokinetic properties of an active pharmaceutical ingredient. However, co-crystal discovery remains both practically challenging and resource intensive, requiring the extensive searching of complex experimental space. Herein, we demonstrate a high-throughput (HTP) nanoscale co-crystallisation method for the rapid screening of large areas of co-crystallisation space with minimal sample requirements, based on Encapsulated Nanodroplet Crystallisation (ENaCt). HTP co-crystallisation screening by ENaCt allowed rapid access to all 18 possible binary co-crystal combinations of 3 small molecules and 6 co-formers (A/B), through the use of 3456 individual experiments exploring solvent, encapsulating oil and stoichiometry, including 10 novel binary co-crystal structures elucidated by single crystal X-ray diffraction (SCXRD). Higher-order co-crystal (HOC) discovery, accessing co-crystals containing three or more molecules, is one of the most challenging co-crystal research areas, due to the highly complex experimental landscape that must be navigated. Herein, we further exemplify the power of ENaCt co-crystallisation by application to HOC discovery. HTP ENaCt co-crystallisation screening of three component (A/B/C) and four component (A/B/C/D) combinations gave ready access to both ternary and quaternary HOCs, each containing three or four different molecular species respectively. In total, 13 056 individual ENaCt experiments are presented resulting in 54 co-crystal structures by SCXRD, including 17 novel binary co-crystals, 8 novel ternary co-crystals and 4 novel quaternary co-crystals. ENaCt co-crystallisation is thus demonstrated to be a highly impactful and efficient tool in the search for small molecule co-crystals, through the employment of parallelised HTP nanoscale experimental workflows.

Identifiers

PMID40321178
PMCPMC12044422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.